Myeloproliferative Neoplasms and Bone Structure
This is a clinical study to evaluate the effect of CMPN to the bone.
Three individual cohorts are defined; a cohort consisting of 50 patients with Polycythemia
Vera (PV), a cohort consisting of 50 patients with Essential Thrombocythemia (ET), and a
cohort consisting of 25 patients with Primary Myelofibrosis (PMF).
Patients are recruited from the Department of Hematology, Odense University Hospital.
Interventions consist of:
- Conventional DXA scan to measure Bone Mineral Density (BMD).
- Experimental HR-pQCT to assess geometry, strength and microstructure of the bone in 3
- Blood-samples are collected and frozen for later analyses of Biochemical Bone Markers:
1-CTP, Ctx, ALP (alkaline phosphatase)and P1NP.
The outcome is compared to healthy control individuals.
Observational Model: Case Control, Time Perspective: Prospective
Bone Mineral Density (BMD)
Patients will undergo one DXA scan independent of time of CMPN diagnosis
Sarah Farmer, MD
Department of Hematology, Clinical Institute, University of Southern Denmark
Denmark: The Danish National Committee on Biomedical Research Ethics